Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 2:09 AM
Ignite Modification Date:
2025-12-25 @ 2:09 AM
NCT ID:
NCT02427360
Eligibility Criteria:
Inclusion Criteria:
* Patients of any age and sex who received treatment for uncomplicated malaria and followed up between January 2003 to December 2013
* Symptomatic of malaria infection, i.e. history of fever or tympanic temperature ≥37.5°c
* Microscopically confirmed asexual stages of P. falciparum ≥ 5/500 WBC (alone or mixed with non- P. falciparum species)
* Received fully supervised treatment of mefloquine-artesunate
Exclusion Criteria:
* Pregnant woman
* P. falciparum asexual stage parasitaemia greater than or equal to 4% red blood cells Signs or symptoms indicative of severe malaria29
* Mefloquine treatment within the 60 days preceding the current episode of malaria
* Splenectomy
Patients will be excluded from the efficacy analysis if they didn't finish the 3 days treatment of mefloquine artesunate but still kept in intention-to-treat population.
Healthy Volunteers:
False
Sex:
ALL
Study:
NCT02427360
Study Brief:
Protocol Section:
NCT02427360